Related content

Aprepitant as salvage antiemetic therapy in breast cancer patients receiving doxorubicin and cyclophosphamide

By Hesketh Paul   Younger Jerry   Sanz-Altamira Pedro   Hayden Melissa   Bushey Julie   Trainor Brian   Krentzin Michael   Nowd Peter   Arnaoutakis Konstantinos   Hesketh Ann  

Supportive Care in Cancer, Vol. 17, Iss. 8, 2009-08 ,pp. : 1065-1070

Springer Publishing Company

Access to resources Recommend Favorite

Safety and Activity of the Combination of Pegylated Liposomal Doxorubicin and Weekly Docetaxel in Advanced Breast Cancer

By Morabito Alessandro  

Breast Cancer Research and Treatment, Vol. 86, Iss. 3, 2004-08 ,pp. : 249-258

Springer Publishing Company

Access to resources Recommend Favorite

Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy

By Leal A.   Kadakia K.   Looker S.   Hilger C.   Sorgatz K.   Anderson K.   Jacobson A.   Grendahl D.   Seisler D.   Hobday T.   Loprinzi Charles  

Supportive Care in Cancer, Vol. 22, Iss. 5, 2014-05 ,pp. : 1313-1317

Springer Publishing Company

Access to resources Recommend Favorite

Doxorubicin versus methotrexate both combined with cyclophosphamide, 5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer-a randomised study with more than 10 years follow-up from the danish breast cancer cooperative gr

By Andersson M.   Lindegaard Madsen E.   Overgaard M.   Rose C.   Dombernowsky P.   Mouridsen H.T.  

European Journal of Cancer, Vol. 35, Iss. 1, 1999-01 ,pp. : 39-46

Elsevier

Access to resources Recommend Favorite

Liposomal Doxorubicin: A Review of its Use in Metastatic Breast Cancer and Potential in Non-Hodgkin Lymphoma

By Dando Toni M.   Keating Gillian M.  

American Journal of Cancer, Vol. 4, Iss. 3, 2005-01 ,pp. : 193-206

Adis International

Access to resources Recommend Favorite